SCHEMBL8047299

SCHEMBL8047299

NC(=O)c1cnn(-c2cccc(Cl)c2Cl)c1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 1/20 0.56
RAB9A P51151 2/20 0.49
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
FGFR1 P11362 4/20 0.48
SRC P12931 4/20 0.48
FGFR2 P21802 4/20 0.48
FGFR4 P22455 4/20 0.48
FGFR3 P22607 4/20 0.48
KDR P35968 4/20 0.48
MAPK14 Q16539 4/20 0.45
TSHR P16473 1/20 0.45
SCN9A Q15858 3/20 0.45
SCN5A Q14524 1/20 0.45
NPC1 O15118 1/20 0.42
PARP1 P09874 1/20 0.41
HTT P42858 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
P2RX7 Q99572 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14692428 0.89 FGFR1 (0.51) RIPK2FGFR1SRCFGFR2FGFR4
SCHEMBL1691442 0.88 RIPK2 (0.63) RIPK2RAB9ALMNASMN1; SMN2FGFR1
SCHEMBL15933282 0.87 SCN9A (0.49) RIPK2LMNAFGFR1SRCFGFR2
SCHEMBL15930138 0.84 FGFR1 (0.45) RIPK2FGFR1SRCFGFR2FGFR4
SCHEMBL1691724 0.84 RIPK2 (0.60) RIPK2RAB9ALMNASMN1; SMN2FGFR1
SCHEMBL14692488 0.81 HTT (0.66) RAB9ALMNASMN1; SMN2TSHRNPC1
SCHEMBL10340609 0.81 TSHR (0.45) RIPK2SMN1; SMN2FGFR1SRCFGFR2
SCHEMBL1691804 0.79 RIPK2 (0.67) RIPK2RAB9ALMNASMN1; SMN2FGFR1
SCHEMBL8043489 0.78 RIPK2 (0.54) RIPK2RAB9ALMNASMN1; SMN2FGFR1
SCHEMBL8044344 0.77 MAPK14 (0.58) RIPK2RAB9ALMNASMN1; SMN2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648085-B2 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-11 US disclosed
US-8648085-B2 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-11 US disclosed
US-20110015193-A1 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-01-20 US disclosed
US-20110015193-A1 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-01-20 US disclosed
WO-2009068617-A1 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS FOR THE TEATMENT OF CNS DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015193-A1 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS PDE9A, PDE7A, PDE1C RIPK2 4088/4885RAB9A 87/4885LMNA 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.